Total
0
Shares
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito - The Market Herald
President & Executive Chairman, Vince Ippolito
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Botanix Pharmaceuticals (BOT) has launched the second phase of its BTX 1801 clinical study for the prevention of surgical site infections (SSIs)
  • Roughly 80 per cent of SSIs are caused by the patient infecting themselves from their own nose where the bacteria can colonise
  • Unfortunately, antibiotics used for nasal decolonisation have become more and more resistant
  • Synthetic cannabidiol has been shown to effectively kill this bacteria
  • These findings support the company's BTX 1801 antimicrobial gel as ideal for preventing SSIs
  • The phase 2 study will evaluate this and first participants are expected to be enrolled early next quarter
  • Company shares remain flat and are trading for 7 cents each

Botanix Pharmaceuticals (BOT) has launched the second phase of its BTX 1801 clinical study for the prevention of surgical site infections (SSIs).

One of the most troublesome resistance forming bacteria in the world is Staphylococcus aureus (Staph). Particularly, Methicillin-resistant Staphylococcus aureus (MRSA) is becoming a significant global concern.

Staph and MRSA are the number one cause of SSIs and roughly 80 per cent of SSIs are caused by the patient infecting themselves from their own nose where these bacteria can colonise.

Unfortunately, antibiotics used for nasal decolonisation have become increasingly resistant, with some hospitals recording resistance rates of up to 95 per cent.

In fact, patients colonised with Staph at intensive care unit admission, had an up to 15 times increased risk for developing pneumonia compared to non-colonised patients.

"Antibiotic resistance continues to be a significant global health issue, with no new classes of antibiotics receiving FDA approval in more than three decades, despite the availability of significant funding initiatives and regulatory incentives," Botanix Executive Chairman and President Vince Ippolito said.

Botanix's BTX 1801 antimicrobial gel has shown to be more effective than the market leading agent, mupirocin, at decolonising MRSA. This combined with previous work showing that MRSA bacteria aren't resistant to cannabidiol, makes BTX 1801 an ideal candidate to prevent SSIs.

Due to these findings, the company's phase 2a study will evaluate safety, tolerability and efficacy of two BTX 1801 formulations to decolonise Staph and MRSA from the nose of 60 healthy adults.

Studies show that one in three people carry Staph or MRSA in their nose on average. Therefore, the phase 2a study population is ideal to determine the efficacy of BTX 1801 for Food and Drug Administration (FDA) registration.

Final preparations for this study are underway and Botanix expects to enrol its first participants early next quarter.

Botanix Pharmaceutical's shares remain flat and are trading for 7 cents each at 12:51 pm AEDT.

BOT by the numbers
More From The Market Herald
Adherium (ASX:ADR) - CEO, Rick Legleiter - The Market Herald

" Adherium (ASX:ADR) nabs supply contract for AstraZeneca study in US

Adherium (ADR) has been awarded a supply contract for an upcoming clinical study by AstraZeneca in the United States.
Dimerix (ASX:DXB) - MD and CEO, Dr Nina Webster - The Market Herald

" Dimerix’s (ASX:DXB) DMX-200 closer to COVID-19 study in India

The Indian regulatory agency has recommended that Dimerix’s (DXB) DMX-200 clinical study in COVID-19 patients be approved.
Antisense Therapeutics (ASX:ANP) - MD and CEO - The Market Herald

" Antisense Therapeutics (ASX:ANP) presents new data, files Australian patent

Antisense Therapeutics (ANP) has presented new data to support its ATL1102 drug and also filed another patent in Australia.
Sigman (ASX:SIG) - CEO and Managing Director, Vikesh Ramsunder - The Market Herald

" Sigma Healthcare (ASX:SIG) appoints new CEO

Sigma Healthcare (SIG) has appointed a new Managing Director and CEO to lead the company.